News archive
Showing 692 results
May 2014
-
Media Release
Novartis presents key advances in cancer research at ASCO and EHA from four new pivotal studies in lung, blood and skin cancers
-
Media Release
Novartis drug Signifor® LAR shows superior efficacy in acromegaly patients not controlled on first generation somatostatin analogues
Acromegaly, an endocrine disorder resulting from elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels, is associated with high mortality(1,2)Phase III data show patients on… -
Media Release
Novartis drug Signifor® LAR shows superior efficacy in acromegaly patients not controlled on first generation somatostatin analogues
April 2014
-
Media Release
Novartis recognized as top ranking company in the US on DiversityInc Top 50 Companies for Diversity list
-- Number one ranking acknowledges Novartis Pharmaceuticals Corporation's commitment to and leadership in diversity and inclusion-- Reflects a decade of effort to embed diversity and inclusion into… -
Media Release
Novartis recognized as top ranking company in the US on DiversityInc Top 50 Companies for Diversity list
March 2014
-
Media Release
Novartis reports new Phase III data showing secukinumab (AIN457) improved moderate-to-severe plaque psoriasis in patients
- FEATURE and JUNCTURE data show secukinumab delivered significant skin clearance at week 12(1,2)- Patients reported high satisfaction with self-administration of secukinumab pre-filled syringe or… -
Media Release
Novartis reports new Phase III data showing secukinumab (AIN457) improved moderate-to-severe plaque psoriasis in patients
-
Media Release
Novartis Announces FDA Approval of Xolair® (omalizumab) for Chronic Idiopathic Urticaria (CIU), a Form of Chronic Hives
- First-in-class medicine approved for CIU, a burdensome skin condition that can cause hives, severe itch, and swelling that can last many months and years- Xolair® is approved for CIU patients age… -
Media Release
Novartis Announces FDA Approval of Xolair® (omalizumab) for Chronic Idiopathic Urticaria (CIU), a Form of Chronic Hives
January 2014
-
Media Release
Novartis Pharmaceuticals Corporation stands behind medication adherence activities and reaffirms commitment to patient safety
Patient safety and well-being are highest priority at Novartis Pharmaceuticals Corporation (NPC) Patient adherence activities provide important education and support to help patients… -
Media Release
Novartis Pharmaceuticals Corporation stands behind medication adherence activities and reaffirms commitment to patient safety